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A B S T R A C T
There is growing evidence that aminobisphosphonates like ibandronate show anticancer activity by an
unknown mechanism. Biochemically, they prevent posttranslational isoprenylation of small GTPases,
thus inhibiting their activity. In tumor cells, activated RAS-GTPase, the founding member of the gene
family, down-regulates the expression of the pro-apoptotic gene FAS via epigenetic DNA-methylation by
DNMT1. We compared ibandronate treatment in neoplastic human U-2 osteosarcoma and in mouse CCL-
51 breast cancer cells as well as in the immortalized non-neoplastic MC3T3-E1 osteoblastic cells.
Ibandronate attenuated cell proliferation in all cell lines tested. In the neoplastic cells we found up-
regulation of caspases suggesting apoptosis. Further we found stimulation of FAS-expression as a result
of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-
isoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate. In contrast,
ibandronate did not affect FAS and DNMT1 expression in MC3T3-E1 non-neoplastic cells. Data suggest
that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic
cells by DNA-CpG-demethylation and stimulation of FAS-expression. In conclusion the shown epigenetic
mechanism underlying the anti-neoplastic activity of farnesyl-transferase-inhibition, also explains the
clinical success of other drugs, which target this pathway.
 2012 Elsevier Inc. 
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The 3rd generation of aminobisphosphonates like alendronate,
risedronate, zoledronic acid, ibandronate and other compounds
affect bone resorption of osteoclasts by inhibiting isoprenylation of
the small GTP-binding proteins and are therefore used as anti-
resorptive treatment of osteoporosis. Additionally to their effects
on bone, there is growing evidence for an anticancer activity of
these drugs [1–8]. However, the mechanisms involved in these
effects remain poorly understood.
Biochemically, aminobisphosphonates act principally by inhi-
biting farnesyl pyrophosphate (FPP) synthase – an enzyme of the
mevalonate pathway – thereby preventing the post-translational
modiﬁcation (prenylation) of small guanosine triphosphate (GTP)-
binding proteins (small-GTPases) that is essential for their
function. Because small GTP-binding proteins modulate nearly
every cellular activity, it is clear that functional inhibition from* Corresponding author at: Ludwig Boltzmann Institute of Osteology, 1st Medical
Department, Hanusch Hospital, Heinrich Collin-Str. 30, A-1140 Vienna, Austria.
Tel.: +43 1 91021 86933; fax: +43 1 91021 86929.
E-mail address: franz.varga@osteologie.at (F. Varga).
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Open access under CC BY-NC-ND license.members of this protein family inﬂuences growth and differentia-
tion of normal cells as well as of tumor cells [3,5,7,9–11].
The founding members of the large family of small-GTPases are
the three RAS-proteins, HRAS, NRAS and KRAS. Activation of the
RAS/RAF/MEK/ERK pathway, for instance by mutation of the
involved GTPases or their regulating members, is responsible for
the development of a plethora of cancers [12–14] and targeting
this pathway seems to be a promising strategy in tumor therapy
[15,16]. The RAS/RAF/MEK/ERK pathway activates DNA-methyla-
tion processes [17–19]. Epigenetic processes include histone
modiﬁcations and methylation of CpGs (cytosine-guanosine
dinucleotides) on the DNA, especially on gene promoters. Changes
of the methylation state of gene promoters lead to alteration in
gene expression patterns. This inﬂuences cellular differentiation
and apoptosis and thus tumor formation (for review see Refs. [19–
22]). DNA methylation dependent inactivation of tumor suppres-
sor genes like cell cycle inhibitors (e.g. CDKN1A, CDKN1B, CDKN2A,
CDKN2B) and LOX (lysyl oxidase) as well of the pro-apoptotic gene
FAS (TNF receptor superfamily, member 6) is often observed during
development of neoplastic diseases. Promoter CpG-hypermethyla-
tion of these genes was found in colon cancers [23], prostate
carcinomas [24–26], breast cancers [27–29] or hematologic
malignancies [30–33]. Consequently, several DNA demethylating
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to reactivate genes such as FAS which plays a key role in
immortality of cancer stem cells [34].
It has recently been shown that activated RAS prevents cellular
apoptosis by epigenetic inhibition of Fas expression through
stimulation of the RAF/MEK/MAPK1 pathway with subsequent Fas
promoter methylation via DNMT1 (DNA-(cytosine-5-)-methyl-
transferase 1), an enzyme responsible for CpG methylation during
cell replication [17]. Similarly, in osteoblasts, extracellular matrix
(collagen type I) preserves CpG-methylation of the Fas promoter
via MAPK1 and DNMT1, thus preventing apoptosis of proliferating
osteoblasts [19]. Although, utmost efforts have been spent to
clarify the relevance and the regulation of cytosine methylation for
physiological and pathological development, only few progresses
have been made until now. The involvement of RAS and other small
GTP-binding proteins in bisphosphonates’ activity and the
knowledge of apoptotic effects on bone cells, also of bispho-
sphonates of the 3rd generation [1,4,6,7,35–37], suggest that these
drugs could modulate CpG-methylation of gene promoters.
Here, we demonstrate that the aminobisphosphonate iban-
dronate modulates the DNA methylation status of the FAS
promoter by inﬂuencing the isoprenylate pathway in human U-
2 osteosarcoma (OS) cells and CCL-51 cells, a murine mammary
gland tumor cell line, but not in non-neoplastic immortalized
MC3T3-E1 cells. Treatment with ibandronate leads to re-
expression of FAS and to increased activity of apoptosis-
associated caspases in the tumor cell lines. Knock down of FAS
mRNA expression by siRNA technique largely re-establishes cell
viability in ibandronate treated neoplastic U-2 OS cells. Our data
suggest that epigenetic mechanisms play a key role in the
apoptotic activity of bisphosphonates, and possibly many of their
effects on cellular physiology including systemic changes within
an organism.
2. Materials and methods
2.1. Cell culture
MC3T3-E1 cells, a clonal pre-osteoblastic cell line derived from
newborn mouse calvaria (kindly donated by Dr. Kumegawa, Meikai
University, Department of Oral Anatomy, Sakado, Japan) and the
human osteosarcoma cell line U-2 OS were cultured in alpha-
minimum essential medium (a-MEM; Biochrom, Berlin, Germany)
supplemented with 50 mg/mL ascorbic acid (Sigma–Aldrich, St.
Louis, MO), 5% fetal calf serum (Biochrom), and 10 mg/mL
gentamycin (Sigma–Aldrich). CCL-51 cells, a murine mammary
gland tumor cell line, were cultured in eagle minimum essential
medium (EMEM, Sigma–Aldrich) supplemented with 292 mg/mL L-
glutamine, 10% fetal calf serum and 10 mg/mL gentamycin. All cells
were cultured in humidiﬁed air under 5% CO2 at 37 8C. For
propagation, cells were subcultured twice a week using 0.001%
pronase E (Roche, Mannheim, Germany) and 0.02% EDTA in Ca2+-
and Mg2+-free phosphate-buffered saline (PBS) before achievingTable 1
Primer sequences.
Gene Forward primer (50–30) 
Primer for gene expression (mouse and human)
Dnmt1 ACCGCTTCTACTTCCTCGAGGCCTA 
Fas TATCAAGGAGGCCCATTTTGC 
Primer for Fas promoter methylation assessment
Mouse CATACCCACAGGCAGTCTAGA 
Human CTGACTCCTTCCTCACCCT 
Primer for DNMT1 chromatin immune-precipitation of the Fas promoter
Mouse CATACCCACAGGCAGTCTAGA 
Human CTGACTCCTTCCTCACCCT conﬂuence. To prevent a potential phenotypic drift during
repeated sub-cultures, the cells were not used for more than 4
weeks after thawing. For experiments, cells were seeded in culture
dishes at a density of 20,000/cm2 as untreated controls or treated
with the indicated compounds at times and concentrations
speciﬁed. Ibandronate, geranylgeranyl-pyrophosphate (GGPP)
and farnesyl-pyrophosphate (FPP) were purchased from Sigma-
Aldrich. Ibandronate was dissolved in water and aliquots were
frozen at 20 8C.
2.2. Cell viability/proliferation
To assess cell metabolic activity, a commercially available, MTT
similar assay (EZ4U; Biomedica, Vienna, Austria) was used. For this
purpose, the cell lines were incubated with increasing concentra-
tions of ibandronate (1–50 mM for MC3T3-E1 and U-2 OS cells or
1–200 mM for CCL-51 cells). After a comparable doubling time for
all three cell lines the assay was performed following the protocol
of the supplier.
2.3. Cell counting
Cells were seeded in 24 multi-well culture dishes at a density of
20,000/cm2 and were either left untreated (controls) or treated
with ibandronate, GGPP and FPP at the indicated concentrations
for 72 h. Thereafter, cells were detached with 0.001% pronase E and
the number of viable cells was assessed with Casy cell counter
(Schaerfe Systems, Germany). Each experiment was performed in
quadruplicate and experiments were carried out twice.
2.4. Measurement of caspase activity
Caspase 3/7 and caspase 8 activities were measured by using
the Caspase-Glo 3/7 and Caspase-Glo 8 assay Kit (Promega, Corp.,
Madison, WI) following manufactures instructions. Brieﬂy, after
treatments, cells were lysed and substrate cleavage by caspases
was measured by the generated luminescent signal with a 96
multi-well luminometer (Glomax, Promega). Each experiment was
performed in quintuplicate and experiments were carried out
twice.
2.5. Isolation of nucleic acids and expression analysis by qRT-PCR
DNA and RNA were extracted using a DNA/RNA Isolation Kit
(Qiagen, Hilden, Germany) following manufacturers instructions.
cDNA was synthesized from 0.5 mg RNA using the 1st Strand cDNA
Synthesis Kit (Roche) as described by the supplier. The obtained
cDNA was subjected to PCR ampliﬁcation with a real-time cycler
using FastStart SYBR-Green Master Mix (Roche) for the genes Fas
and Dnmt1 (primers are shown in Table 1). The qRT-PCR was
performed with 45 cycles composed of 30 s denaturation at 95 8C,
30 s annealing at the indicated temperature (Table 1) and 30 s
extension at 72 8C after 10 min of initial denaturation at 95 8C. ForReverse primer (50–30) Tm (8C)
GTTGCAGTCCTCTGTGAACACTGTGG 62
TGTTTCCACTTCTAAACCATGCT 64
CAGCCCAGAGTAACTCACTTC 62
CTTCCCCAACTCCGTACT 64
CAGCCCAGAGTAACTCACTTC 62
CTTCCCCAACTCCGTACT 62
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(4319413E, Applied Biosystems, Forster City, CA) in the respective
master mix according to the suppliers suggested conditions (Applied
Biosystems). All PCRs were performed in triplicate and expression
was evaluated using the comparative quantitation method [38]. For
each of the three time independent biological replicates, the
triplicate results of the qRT-PCR were averaged and this mean
value was treated as a single statistical unit.
2.6. FAS siRNA transfection
For FAS depletion by siRNA, U-2 OS cells were seeded at
20,000 cells/cm2 in a 48-multi-well plate and transfected with
100 nM of a mixture of two FAS siRNAs (SASI_Hs01 00079050,
SASI_Hs01_00079052, Sigma–Aldrich) by electroporation using
the Neon Transfection System (Invitrogen) following supplier’s
protocol. Next day cells were treated with 7.2 mM ibandronate
(EC50). After 72 h of incubation, cell metabolic activity was
measured with the EZ4U assay as described above. Furthermore to
control FAS mRNA and protein knockdown, cells were seeded in a
six-multi well plate or 5 cm petri dish at 20,000 cells/cm2 and
transfected with the FAS siRNA as described above. 96 h after
transfection mRNA or protein was isolated as described above and
below and FAS mRNA and protein expression was measured by
qRT-PCR and immune-blot, respectively.
2.7. Protein isolation and immune blotting
For whole cell protein extraction, cells were washed twice with
PBS, scraped in SDS sample buffer (2% SDS, 100 mM b-mercap-
toethanol, 125 mM Tris–HCl, pH 6.8) heated at 95 8C for 5 min and
sonicated for further 5 min. To divide cell proteins into cytosolic
and membrane fractions, cells were detached from culture vessels
washed with PBS and incubated in hypotonic buffer (10 mM HEPES
pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) for
10 min on ice. Then, cells were broken by 20 strokes in a Dounce
homogenizator and suspensions were centrifuged at 3300  g for
20 min at 4 8C. Supernatants were centrifuged for another 30 min
at 15,000  g at 4 8C and the supernatants thus obtained were
saved as cytosolic fraction. The pellets were dissolved in SDS
sample buffer constituting the membrane fraction. Protein content
was measured with Coomassie protein assay (Thermo Fisher
Scientiﬁc, Waltham, MA) or with bicinchoninic acid assay (Sigma–
Aldrich) for the SDS extracts. For immune-blotting 30 mg of protein
extracts for RAS and FAS or 50 mg of protein extracts for DNMT1
were fractionated on 12%, 10% or 8% SDS-PAGE, respectively.
Following SDS-gel electrophoresis, the proteins were transferred to
nitrocellulose ﬁlters (Millipore) and blocked overnight with 10%
blocking reagent (Roche Applied Science, Mannheim, Germany) in
TN Buffer (50 mM Tris, 125 mM NaCl, pH 8). Subsequently, the
ﬁlters were incubated for 1 h at room temperature with an
antibody against DNMT1 (K-18, Santa Cruz Biotechnology, Santa
Cruz, CA), against FAS and against RAS (610197 and 610002, BD
Transduction LaboratoriesTM) all diluted 1:200 in blocking buffer.
Afterwards, ﬁlters were washed three times with immune blot
wash buffer (TN buffer containing 0.01% Tween) and incubated for
an additional hour with an anti-goat IgG HRP-labeled secondary
antibody (Sigma–Aldrich) diluted 1:160,000 in blocking buffer or
with an anti-mouse IgG/anti-rabbit IgG horseradish peroxidase
(HRP)-labeled secondary antibody (Roche) diluted 1:10,000 in the
blocking buffer, respectively. Finally, the blots were washed again
three times with immune-blot washing buffer before detection of
light emission with the BM chemiluminescence immune blotting
kit (Roche Applied Science) as described by the supplier.
Chemiluminescence was measured with an image acquisition
system (Vilber-Lourmat, France).Cell fractionation was controlled by immunoblotting using
antibodies against integrin-b5 (ITGB5, H-96, Santa Cruz Biotech-
nology, Santa Cruz, CA) for the membrane and mitogen-activated
protein kinase 4 (MAPK4, Transduction Laboratories, BD, Franklin
Lakes, NY) for the cytosolic fraction (Suppl. Fig. 3).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bcp.2012.10.016.
2.8. Speciﬁc promoter methylation
To analyze Fas promoter 5-methylcytosine levels, appropriate
fragments of the targeted promoter regions were generated by
digestion of 1 mg of genomic DNA with 20 U of the CpG
methylation insensitive restriction enzymes MboII (Promega) or
PstI (Fermentas, St. Leon-Rot, Germany) (for the murine or for the
human Fas gene, respectively) for 1 h at 37 8C from cells cultured
for 24, 48 and 72 h with 50 mM ibandronate in the medium.
Subsequently, the enzyme was heat inactivated at 65 8C for 20 min.
The Fas promoter region was selected as shown before [39]. In
brief, in the murine cell lines two CpG rich regions were analyzed,
the ﬁrst at 2.6 kb and the second starting at 30 bp upstream from
the Fas transcriptional start site (TSS) [17,19]. In the human
osteosarcoma cell line, a CpG rich region of the proximal FAS
promoter region was analyzed [19]. This fragment spanned from
79 bp upstream from the TSS into 359 bp of the ﬁrst exon and
showed an overall CpG content above 50%. PstI digestion generated
a suitable fragment of 942 bp covering the CpG rich region. After
digestion, DNA was puriﬁed using a commercially available PCR
clean-up kit following the supplier’s instructions. In the next step
methylated DNA fragments were captured using the ‘‘MethylMiner
Methylated DNA Enrichment Kit’’ (Invitrogen). In brief, methylated
DNA was captured by methyl-CpG binding domain protein 2
(MBD2) coupled to magnetic beads to separate the modiﬁed from
the non-modiﬁed DNA fractions. DNA was eluted from the
magnetic beads with 200 mL of 2 M NaCl solution as single
fraction independent from the CpG methylation density and
concentrated by ethanol precipitation. Finally, the mean methyla-
tion status of the fragments was determined by amplifying the
fragments by quantitative real-time PCR. Ampliﬁcation ratios of
the bound (methylated) DNA fraction to unbound (unmethylated)
DNA fraction were calculated (for primer design see Table 1).
2.9. DNMT1 chromatin immune precipitation (ChIP) on Fas promoter
For this purpose, cells were treated with 50 mM ibandronate for
72 h. Subsequently, chromatin cross-linking, cell lysis, chromatin
sharing, DNMT1 immune precipitation and DNA clean up were
performed with the ChampionChip one-day kit (SABiosciences,
Hilden, Germany) following manufacturer’s instructions. Thereby,
chromatin from untreated as well as from ibandronate treated cells
was incubated overnight on a rotor at 4 8C with 4 mg of anti-DNMT1
antibody (K-18, Santa Cruz Biotechnology, Santa Cruz, CA) or with
4 mg of non-immune serum as negative control. Before immune
precipitation, 1% (10 mL) of the chromatin was saved and stored at
4 8C for further use as reference. DNMT1 binding on appropriate FAS
promoter regions was measured by qRT-PCR (for ChIP-FAS promoter
primers see Table 1). For quantitation of the qRT-PCR values, for each
sample, DNA signal of the DNMT1-precipitated chromatin was
normalized to the unprecipitated chromatin.
2.10. Statistical analysis
Statistical analyses were performed either with ANOVA or with
Student’s t-test using Prism 4.03 (GraphPad Software, San Diego,
CA), P  0.05 was considered as signiﬁcant. The data of the
experiments are presented as means  standard deviation (SD).
Fig. 1. Ibandronate attenuated cell viability/proliferation and regulated caspases 3/7 and 8. After 3 days treatment ibandronate attenuated cell multiplication with a half
maximal effect (EC50) at 6.8 mM (95% c.i.: 6.00–7.67 mM) in MC3T3-E1 cells (A) and 7.21 mM (95% c.i.: 5.90–8.79 mM) U-2 OS cells (B), while in CCL-51 a slightly higher
concentration of 14.4 mM (95% c.i.: 14.0–14.9 mM) (C) was necessary to show the same effect. After the same treatment time, ibandronate down regulated caspase 3/7 in
MC3T3-E1 cells signiﬁcantly already at a concentration of 20 mM, while a signiﬁcant down-regulation of 8 was found not until a concentration of 100 mM (D). In U-2 OS (E)
and CCL-51 (F), however, ibandronate up regulated both caspases at all concentrations tested. Bars represent mean  SD; **P  0.01; ***P  0.001; n = 4.
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3.1. Effects of ibandronate on cell multiplication and caspases
activities
After 72 h of treatment, ibandronate attenuated cell multipli-
cation in all cell lines tested, although with different half maximal
effective concentrations (EC50, Fig. 1A–C). Using a MTT-like assay
to assess cell viability/proliferation, in the bone related cells
MC3T3-E1 (Fig. 1A) and U-2 OS (Fig. 1B), ibandronate showed a
comparable half maximal effect (EC50) with 6.8 mM (95% c.i.:
6.00–7.67 mM) and 7.21 mM (95% c.i.: 5.90–8.79 mM), respective-
ly, while the CCL-51 cells (Fig. 1C) were less sensitive with an EC50
of 14.4 mM (95% c.i.: 14.0–14.9 mM). Using cell counting only
approximate similarities were found for the three cell-lines. This
may be explained by the strong changes in cell morphology after
ibandronate treatment, which makes it difﬁcult to determine, if a
cell is still viable (Suppl. Fig. 1A–C).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bcp.2012.10.016.
In MC3T3-E1 cells, caspase 8 and particularly caspase 3/7
activities were reduced after 72 h of ibandronate treatment in a
concentration dependent manner showing signiﬁcance at 20 mM
for caspase 3/7 and at 100 mM for caspase 8 (Fig. 1D). An opposite
effect was seen in the two tumor cell lines analyzed: caspase 8 as
well as caspase 3/7 activities were signiﬁcantly increased after
72 h of ibandronate treatment in human U-2 OS osteosarcoma cells
(Fig. 1E) as well as in murine CCL-51 breast tumor cells (Fig. 1F).
3.2. Ibandronate up regulated FAS expression in a time and dose
dependent manner, which was responsible for down regulation of cell
viability/proliferation
In line with the effects observed on caspase activities,
ibandronate failed to signiﬁcantly regulate the mRNA expression
of the pro-apoptotic gene Fas in MC3T3-E1 cells at any time
(Fig. 2A) and after 72 h at any concentration tested (Fig. 2B). Incontrast, already after 24 h of treatment, FAS mRNA expression was
strongly induced in U-2 OS cells (Fig. 2C) and after 48 h in CCL-51
cells (Fig. 2E). This stimulation was dose dependent but showed
signiﬁcance only at concentrations of 100 mM in U-2 OS cells
(Fig. 2D) or higher than 20 mM in CCL-51 cells (Fig. 2F).
To demonstrate the role of FAS in ibandronate induced
apoptosis, U-2 OS cells were transfected with FAS siRNA by
electroporation and cell viability/proliferation was measured with
the MTT-like assay (Fig. 3A). In ibandronate treated cells, a
difference of 19.2% in down regulation of cell viability/proliferation
was measured between electroporation of unexposed and
electroporation of exposed cells, which suggest that electropora-
tion makes cells more sensitive to ibandronate. This assumption is
supported by a similar effect found by transfection of the control
siRNA. Transfection of FAS siRNA recovered cell viability/prolifera-
tion to a large extent (87%), suggesting that a second, minor
process is involved in down-regulation of cell viability/prolifera-
tion too. FAS knock down by siRNA was controlled by FAS mRNA
expression (Suppl. Fig. 2).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bcp.2012.10.016.
Translation of the FAS mRNA expression to the protein level is
demonstrated in Fig. 3B. Protein extracts isolated from FAS siRNA
transfected cells, which were either left untreated or treated with
ibandronate for 72 h, were subjected to immune-blotting and
probed with an anti-FAS antibody. Similarly to mRNA regulation,
when compared to controls, ibandronate up regulated FAS protein
expression. FAS siRNA transfected cells, however, showed no
signiﬁcant difference to controls, neither untreated nor ibandro-
nate treated.
3.3. Differential regulation of Dnmt1 expression by ibandronate
Similar to Fas expression, ibandronate failed to affect Dnmt1
expression in MC3T3-E1 cells at any time (Fig. 4A) and after 72 h at
any concentration (Fig. 4B) tested. However, Dnmt1 expression
was clearly down regulated in both tumor cell lines. In U-2 OS cells
Fig. 2. Ibandronate up regulated FAS expression in U-2 OS and CCL-51 but not in MC3T3-E1 cells (A and B). At 100 mM ibandronate up regulated FAS expression in U-2 OS
already after 24 h (C) while in CCL-51 not until 48 h (E). In both cell lines the regulation was dose dependent, which reached signiﬁcance at 100 mM in U-2 OS (D) and at 50 mM
in CCL-51 (F). Bars represent mean  SD; *P  0.05; **P  0.01; n = 3.
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cells signiﬁcance was reached after 72 h of treatment with 50 mM
ibandronate (Fig. 4E). At this time, in U-2 OS cells, DNMT1
expression was already strongly down regulated at 20 mM
ibandronate in culture medium (Fig. 4D) whereby a comparable
effect was reached at 100 mM ibandronate for CCL-51 cells
(Fig. 4F). Fig. 6G and H compares the effect of 72 h of treatment
with 50 mM ibandronate on DNMT1 protein expression by
immune blot analysis in the three cell lines studied.
3.4. Fas promoter methylation was altered in tumor cells after
ibandronate treatment
72 h after seeding, in MC3T3-E1 cells basal Fas promoter
methylation was considerably lower as in the two neoplastic cell
lines (Table 2). Furthermore, in MC3T3-E1 cells, 72 h of 50 mM
ibandronate treatment failed to signiﬁcantly affect DNMT1 bindingon Fas promoter (Fig. 5A). After 72 h, in U-2 OS cells (Fig. 5C) as well
as in CCL-51 cells (Fig. 5E) treatment with ibandronate signiﬁcant-
ly reduced binding of DNMT1 to the FAS promoter.
Reduced binding of DNMT1 to the Fas promoter suggested
changes in DNA methylation, which was evaluated by comparing
the concentration of methyl-cytosines vs. unmethylated cytosines
in the promoter. While as expected, no change in the methylation
status of the Fas promoter in MC3T3-E1 cells was found (Fig. 5B),
ibandronate signiﬁcantly reduced the methyl-cytosine concentra-
tion of the Fas promoter in U-2 OS already after 24 h (Fig. 5D) and
after 48 h in CCL-51 cells (Fig. 5F).
3.5. Ibandronate altered RAS localization in the analyzed tumor cell-
lines
Bisphosphonates inhibit the activities of the enzymes farnesyl-
and geranylgeranyl-diphosphate synthase, which cause disruption
Fig. 3. Ibandronate down regulated cell viability/proliferation and up regulated FAS,
which could be rescued by transfection of FAS siRNA. (A) After 3 days of treatment
with ibandronate (7.2 mM, EC50) cell viability/proliferation was down regulated to
73.6% (control). After electroporation without siRNA ibandronate down regulated
cell viability/proliferation to 54.4% (Electrop.) a comparable value, which was found
after electroporation of a control siRNA (56.4%, Co siRNA). Electroporation of FAS
siRNA resulted in attenuation of down-regulation of cell viability/proliferation to
87.0% demonstrating the FAS regulation on this parameter. The difference of 13.0%
suggests a minor second mechanism on regulation of cell viability/proliferation.
Bars represent mean  SD; **P  0.01; ***P  0.001; untreated vs. Iban treated;
+++P  0.001; Co siRNA vs. FAS siRNA; n = 3. (B) The immune-blot with anti-FAS
antibody demonstrates that Ibandronate up regulated FAS protein expression as well.
Transfection with FAS siRNA down regulated ibandronate stimulated FAS protein
expression having no considerable effect on basal FAS expression.
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distribution. Cells were either left untreated or treated with
ibandronate. Thereafter, proteins of the membrane as well as of
cytoplasmatic fraction were isolated and subjected to immune
blotting. As shown in Fig. 6A, in MC3T3-E1 cells RAS was primarily
localized in the cytoplasm and, therefore, ibandronate did not
affect RAS localization in this cell-line. In U-2 OS cells (Fig. 6B) as
well as in CCL-51 cells (Fig. 6C) RAS was primarily localized in cell
membranes. After exposure to 50 mM ibandronate for 72 h, in both
cell lines a clear shift in RAS localization from the cell membranes
to cytoplasm was seen (Fig. 6B and C).
Cell fractionation was controlled by immune blotting of
integrin-b5 for the membrane and mitogen-activated protein
kinase 4 for the cytosolic fraction (Suppl. Fig. 3).
3.6. Bisphosphonate induced apoptosis of tumorigenic cells was
differentially rescinded by GGPP and FPP
Inhibition of prenylation of small-GTPases by bisphosphonates
can be rescued by parallel treatment with the substrate FPP for RAS
or GGPP for the other modiﬁed small-GTPases.
As already shown in Fig. 1 and Supplemental Fig. 1, treatment of
MC3T3-E1 cells with 50 mM ibandronate reduced the cell number
by about 90%. After the same culture time 10 mM GGPP by itselfattenuated cell multiplication by about 50% and could only
partially rescue the effect of ibandronate on these cells (Fig. 7A). In
U-2 OS cells 50 mM ibandronate signiﬁcantly reduced cell
multiplication. Although GGPP itself reduced cell multiplication
by about 25%, it could rescue the effect caused by ibandronate
(Fig. 7B). Similarly, in CCL-51 cells GGPP could rescue ibandronate
attenuated cell multiplication but, differentially, did only margin-
ally inﬂuence cell multiplication (Fig. 7C). In MC3T3-E1 cells
neither ibandronate nor GGPP inﬂuenced Fas expression (Fig. 7D).
Again, in both other studied cell lines ibandronate induced FAS
expression. GGPP alone had no signiﬁcant effect on FAS expression,
but down regulated ibandronate induced FAS expression in both U-
2 OS (Fig. 7E) as well as in CCL-51 cell lines (Fig. 7F). Regarding
DNMT1 expression, again all three treatments (ibandronate, GGPP
or combination of both) showed no effect in MC3T3-E1 cells
(Fig. 7G). However in both tumor cell lines, ibandronate, as
expected, down regulated expression of DNMT1. GGPP counter-
acted this effect and had no effect when administered singularly
(Fig. 7H and I). This supports our hypothesis that small-GTPases
induce DNMT1 expression is inhibited by bisphosphonates leading
to promoter demethylation and FAS expression.
Next we tested the effects of FPP (40 mM) on cell multiplication
(Fig. 8). In the immortalized MC3T3-E1 cell line (Fig. 8A), FPP
reduced cell number to 63%, in U-2 OS cells to 71% (Fig. 8B) while it
did not affect this parameter in CCL-51 cells (Fig. 8C). However, in
contrast to GGPP, FPP could not rescue the down-regulation of cell
multiplication by ibandronate (Fig. 8A–C). The effects of FPP on
FAS expression were comparable to that of GGPP: no signiﬁcant
effects in MC3T3-E1 cells (Fig. 8D), while in both neoplastic cell
lines (Fig. 8E and F) 40 mM FPP rescued the ibandronate mediated
up-regulation of FAS. Comparable effects were also found on
DNMT1 expression with no effects in MC3T3-E1 cells (Fig. 8G),
while in U-2 OS FPP rescued the down-regulation of DNMT1
expression by ibandronate (Fig. 8H). Differentially, FPP did not
change the attenuation of Dnmt1 expression in CCL-51 cells
(Fig. 8I). FPP alone did not affect DNMT1 expression in any one of
these cell lines.
4. Discussion
A growing body of evidence attributes an anti-tumorigenic
capacity to bisphosphonates. Several studies have shown that in
patients affected by diverse malignances, bisphosphonate thera-
pies show a positive outcome with regard to tumor growth and
metastatic activity [40–46]. However, the mechanisms underlying
those effects remain poorly understood.
By activation, the Ras superfamily of small GTPases attaches to
cellular membranes and, among many other cell regulatory
functions, promotes cell proliferation, differentiation and survival
[12,16,47]. Aminobisphosphonates exert their pharmacologic
activity by inhibiting the mevalonate pathway. By this way, these
drugs prevent prenylation of small-GTPases as well as their
attachment to the cellular membranes and thereby their function
[5,7,48]. While the apoptotic impact of simple bisphosphonates
(clodronate and etidronate) can be considered as secured, the
mode of action of aminobisphosphonates on cells is not as clear
[9,11,49,50]. Initially, J774 macrophages have been considered as a
model of aminobisphosphonates’ action because this cell line
matched the order of potency of the diverse bisphosphonates for
inhibiting bone resorption and inducing apoptosis [7,51–53].
However using primary rabbit or human derived osteoclasts, it has
been demonstrated that inhibition of bone resorption by bispho-
sphonates does not require osteoclast apoptosis [54–56]. Taking
into account that J744 are lymphoma-derived tumorigenic cells
[57] one can conclude that bisphosphonates act in tumor cells in a
different way as compared to normal osteoclasts.
Fig. 4. Ibandronate down regulated DNMT1 expression in U-2 OS and CCL-51 but not in MC3T3-E1 cells (A and B). At 100 mM ibandronate down regulated DNMT1 expression
in U-2 OS already after 24 h (C) while in CCL-51 attenuation did not reach signiﬁcance until 72 h (E). In both cell lines the regulation was dose dependent, which reached
signiﬁcance already at 20 mM in U-2 OS (D) and but not until 100 mM in CCL-51 (F). DNMT1 was also down regulated at the protein level as demonstrated by immuno-blot.
Intensity measurements of 3 immune-blots revealed a signiﬁcant down-regulation only for U-2 OS and CCL-51 cells but not for MC3T3-E1 cells (G). A representative blot is
shown in (H). Bars represent mean  SD; *P  0.05; **P  0.01; ***P  0.001; n = 3.
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Table 2
Methylation levels (ratio methylated vs. unmethylated) of the FAS promoters in the
studied cell lines.
Cell line Methylation level
MC3T3-E1 0.0021  0.012
CCL-51 15.3  4.2
U2OS 3.10  0.63
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non neoplastic immortalized mouse preosteoblastic MC3T3-E1
cells, ibandronate attenuated cell multiplication by down-regula-
tion of the cell cycle as suggested by decreased expression of
cyclins Ccn2a and Ccn2d (not shown). Moreover, down-regulation
of caspase 3/7 and caspase 8 in MC3T3-E1 cells assigned to
aminobisphosphonates an anti-apoptotic activity as found in MLO-
Y4 osteocytes [58] while in tumorigenic RAW 264.7 macrophages
most bisphosphonates induced apoptosis [59]. In primary human
osteoblasts at concentrations higher than 107 M zoledronate dose
dependently reduced cell proliferation, although, at the highestFig. 5. DNMT1 bound to the FAS promoter, which resulted in change of the DNA meth
ibandronate signiﬁcantly reduced binding of DNMT1 to the promoter of FAS in U-2 OS ce
already after 24 h (D). In CCL-51 cells ibandronate attenuated binding of DNMT1 to the Fa
represent mean  SD; *P  0.05; n = 3.concentration apoptosis was found as well [37]. Treatment of fetal
immortalized osteoblasts with pamidronate and zoledronate
resulted in a dose dependent down-regulation of cell proliferation
with increased differentiation [60]. However, increased cell
proliferation of human primary trabecular bone cells [61] and of
human bone marrow stromal cells by alendronate and risedronate
has been reported as well [62]. Summarizing these ﬁndings, in
normal mesenchymal bone cells, bisphosphonates decrease
proliferation but apoptosis was found only at very high concen-
trations, while in tumorigenic cells amino-bisphosphonates induce
apoptosis.
Here we show that treatment of tumor cell lines with
ibandronate down regulated genes of the DNA CpG-methylation
apparatus (Dnmt1, Dnmt3b, Hells), which resulted in reduced
binding of DNMT1 at the promoter of FAS in both tumor cell lines.
Absence of the DNA-methyltransferases at the promoter results in
reduced CpG-methylation of the promoter during further cell
divisions, which is followed by increased expression of the gene
[63–65]. Increased expression of FAS is followed by increased
activity of caspase 3/7 and caspase 8, which is a classical sign ofylation status in U-2 OS and CCL-51 but not in MC3T3-E1 cells (A and B). 50 mM
lls (C) which resulted in a decreased ratio of methylated by unmethylated cytosines
s promoter as well (E) but it decreased methylation not until 48 h treatment (F). Bars
Fig. 6. Ibandronate translocated RAS from the membranes to the cytoplasm in U-2
OS (B) and CCL-51 (C) but not in MC3T3-E1 cells (A). Intensity measurements of 3
immune-blots revealed a signiﬁcant change in the localization of RAS in U-2 OS and
CCL-51 cells but not in MC3T3-E1 cells (A). For each cell line a representative blot is
shown. Bars represent means normalized to the signal of untreated cells  SD;
*P  0.05; **P  0.01; n = 3.
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of Fas expression was found in non-neoplastic MC3T3-E1 cells. The
very low basal methylation level of Fas promoter in these cells can
explain this fact. We have recently demonstrated that culturing
these cells on culture dishes that are not covered by collagen
results in down-regulation of DNMT1 and HELLS followed by
demethylation of the Fas promoter and increased expression of the
gene [19].
Small-GTPases play a central role in bisphosphonates’ activity.
These drugs inhibit the activity of the enzymes, which are
responsible for synthesis of FPP and GGPP, which are transferred
to the amino acids motif CAAX anchoring of the small-GTPases to
the cell membrane, which is a prerequisite for their action. Effects
of bisphosphonates on small-GTPases mediated signal transduc-
tion can be rescued by co-treatment with GGPP or FPP, where in
general FPP rescues RAS-activity and GGPP the activity of the RHO-
and RAB-family [66,67]. Again, transformed cell lines behaved
differentially; in CCL-51 and U-2 OS, GGPP rescued ibandronate
attenuated cell multiplication, up regulated DNMT1 and, conse-
quently, down regulated FAS expression. GGPP, however, could not
rescue the immortalized non-neoplastic cell line MC3T3-E1 from
the effects of ibandronate. We found no down-regulation of Dnmt1
and no up-regulation of Fas. Moreover, GGPP alone signiﬁcantly
decreased cell multiplication as well. GGPP is the posttranslational
modiﬁer of the RHO- and RAB-small-GTPases. Recently, it has been
demonstrated that inhibition of prenylation by bisphosphonates
rather activates than inactivates the RHO family of small-GTPases
including RAC, CDC42 and RHO [9]. Interestingly, osteoblast-
restricted Rac1 deletion leads to defective bone acquisition in vivo
and knockdown impairs growth and induces apoptosis in the
osteoblast cell line OP9 [68]. These data suggest that GGPP
increases interaction of RAC1 with cellular membranes, which
results in reduced activated RAC1 leading to decreased prolifera-
tion and increased apoptosis.
A down-regulation of cell multiplication was also found in
mesenchymal MC3T3-E1 and U-2 OS cells by FPP but not in the
neoplastic cell line resulting from an epithelial tumor. Down-
regulation of cell multiplication by FPP suggests the involvement
of RAS. After translation, FAS is farnesylated and transported to the
endoplasmatic reticulum where it is prepared for palmitoylation
and forwarded to the Golgi-membranes. This initiates a cycle of
trafﬁc to and from the plasma membranes, where it is activated
[13,16]. Higher cellular concentrations of FPP could inﬂuence the
equilibrium of this cycle and therefore alter differentiation,
proliferation and apoptosis rate.
Unlike GGPP, FPP could not rescue down-regulation of cell
multiplication by ibandronate in U-2 OS and CCL-51. This suggests
that RHO- and RAB-small-GTPases are responsible for ibandro-
nate’s effect on this parameter. This is surprising because in U-2 OS,
FPP canceled the effect on DNMT1 expression and inhibited up-
regulation of FAS. An explanation is down-regulation of the cell
cycle by ibandronate via down-regulation of cyclins and a possible
up-regulation of cell cycle inhibitors [68–71]. From the rescue-
experiments one can conclude that ibandronate inhibits cell
multiplication by decreasing cell cycling and by increasing
apoptosis. Apart from apoptosis a second process was also
suggested by transfection of FAS siRNA, which could not completely
recover ibandronate’s down-regulation of cell viability/prolifera-
tion. However, this experiment strengthens our hypothesis that
up-regulation of FAS is responsible for induction of apoptosis via
caspases and conﬁrms recent data obtained from HMC1 mast cell
leukemia cells that were treated with demethylating drugs [34].
Although FPP and GGPP differentially inﬂuenced cell multipli-
cation, unexpectedly, except for Dnmt1 expression in CCL-51, no
differences were found in rescuing FAS and DNMT1 expression;
both isoprenoids could recover the effects of ibandronate, which is
Fig. 7. Effects of GGPP on ibandronate regulated cell multiplication and expression of FAS and DNMT1. Ibandronate down regulated cell multiplication in all three cell lines
tested. In MC3T3-E1 cells, GGPP itself attenuated cell multiplication but could not prevent ibandronate’s down-regulation (A). In U-2 OS (B) and CCL-51 (C) cells, GGPP
rescued down-regulation of cell multiplication. Moreover, the combination of both drugs increased cell multiplication in CCL-51 cells signiﬁcantly (C). Neither ibandronate
nor GGPP had an effect of Fas (D) and Dnmt1 (G) expression in MC3T3-E1 cells. In U-2 OS cells, GGPP rescued ibandronate’s up-regulation of FAS (E) or down-regulation of
DNMT1 (H), respectively. Equally, in CCL-51 cells, GGPP rescued ibandronate’s up-regulation of Fas (F) or down-regulation of Dnmt1 (I), respectively. Bars represent
mean  SD; *P  0.05; **P  0.01; ***P  0.001 treatment vs. Co; +++P  0.001 GGPP vs. Ibn; P  0.05; P  0.001 GGPP vs. Ibn + GGPP; ###P  0.001 Ibn vs. Ibn + GGPP; n = 3.
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recover bisphosphonates-induced apoptosis. There are several
possible explanations for this ﬁnding [11]. Bisphosphonates are,
with some exceptions [72,73], inhibitors of FPP-synthase but not of
the GGPP-synthase. Therefore, when cells were treated with FPP
some of the compounds will be converted to GGPP, which will
modify and rescue RHO-family small-GTPases as well, at least
partially [11]. Recently, it has been demonstrated that in presence
of inhibition of farnesyltransferase, geranylgeranylation occurs
instead of farnesylation of KRAS4A,B and NRAS but not for HRAS.
Moreover, geranylgeranyltransferase can use FPP as substrate as
well to modify proteins of the RHO-family [74–80]. As bispho-
sphonates deplete both FPP and GGPP, raising the concentration of
one of the isoprenoids by addition, modiﬁcation with the ‘‘wrong’’
modiﬁer may occur. These facts may support a critical view on the
implication of the rescue experiments, so that no unambiguous
assignment of a small-GTPase can be made. Even though the
presented results clearly demonstrate the involvement of small-
GTPases in the epigenetic DNA methylation process and FAS
mediated apoptosis, a detailed analysis of the large family of small-
GTPases will be necessary to unravel the mechanism.
Taken together, our experiments support the common knowl-
edge that more members of the group of small-GTPases are
involved in the regulation of cell multiplication and apoptosis andsuggest a different mode of action of bisphosphonates in non-
transformed vs. neoplastic cell lines, as supported by previous
ﬁndings [10,81].
As already mentioned above, most tumors or transformed
neoplastic cells are characterized by an activated RAS/MAPK
pathway [13–15], which results in methylation of cytosines in the
promoter of tumor suppressor genes and of the pro-apoptotic FAS
gene [12,24,30,32,33,82,83]. Both tumor cell lines, however, have a
highly methylated FAS promoter, and therefore, an inhibited FAS
expression. This suggests that RAS must be activated and attached
to the cell membrane to enable bisphosphonates to display their
epigenetic activity. Ibandronate, as demonstrated by immune-
blotting, prevented RAS from attachment to membranes and
translocated the protein into the cytoplasm; no change was found
in MC3T3-E1 cells indicating that RAS is not attached to
membranes, and therefore not or only marginally active, as
generally found in normal, growth factor-unstimulated cells
[47,84]. Our results could explain why tumor cells react
differentially in response to bisphosphonates when compared
with normal cells. It should be emphasized again that activation
RAS/MAPK pathway seems to be a prerequisite for bispho-
sphonates’ action in tumor cells. Featuring the RAS/MAPK pathway
is well founded by the fact that epigenetic silencing of the Fas
promoter is a consequence from the signaling cascade of this
Fig. 8. Effects of FPP on ibandronate regulated cell multiplication and expression of FAS and DNMT1. Ibandronate down regulated cell multiplication in all three cell lines
tested. In MC3T3-E1 and U-2 OS cells, FPP itself attenuated cell multiplication (A and B) but had no effect on CCL-51 cells (C). FPP could not rescue cell multiplication in these
cell lines. Neither ibandronate nor FPP had an effect on FAS (D) or DNMT1 (G) expression in MC3T3-E1 cells. In U-2 OS cells, FPP rescued ibandronate’s up-regulation of FAS (E)
or down-regulation of DNMT1 (H), respectively. In CCL-51 cells, FPP rescued ibandronate’s up-regulation of Fas (F) but not down-regulation of Dnmt1 (I), respectively. Bars
represent mean  SD; *P  0.05; ***P  0.001 treatment vs. Co; +++P  0.001 FPP vs. Ibn; P  0.001 FPP vs. Ibn + FPP; n = 3.
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addition to RAS, other members of small-GTPases must be involved
in regulation of FAS promoter methylation as well. Differences in
responses to ibandronate of the epithelial CCL-51 cells compared to
the mesenchymal cells suggest involvement of RAC1, a gene that has
been found important for osteoblastic proliferation, differentiation
and apoptosis [68]. The use of speciﬁc inhibitors of small-GTPases
will help to clarify the mechanism of the selective epigenetic
activation of FAS and other epigenetic silenced tumor suppressor
genes [8,15]. It should be emphasized that other inhibitors of small-
GTPases may demonstrate epigenetic mechanisms as well.
A recent publication has demonstrated that bisphosphonate pulse
treatment differentially affects mesenchymal stem cells [66]. Passive
demethylation of a gene promoter needs at least one or two cell
cycles. Short treatment of cells will activate promoter demethylation,
which then will be inherited to the daughter cells, where apoptotic
factors could further activate the demethylated FAS gene.
Methylation of tumor suppressor genes is a common mecha-
nism in tumor development. Loss of hormone responsiveness in
breast and prostate cancer as well as in leukemias may contribute
to increased mortality that often happens by CpG-methylation of
promoter DNA [25,26,28,29,85,86] and drugs decreasing CpG-
methylation are promising for future treatment of such tumors.
Our ﬁndings could possibly explain some contradictory results in
clinical trials using bisphosphonates combined with an adjuvantendocrine therapy [40,87]; only a subgroup of patients with an
epigenetic inactivated estrogen receptor ESR1 seems to respond to
this therapy via RAS/MAPK pathway.
In summary, we demonstrated that ibandronate is an epige-
netically active drug. In tumor cells it inhibits activated RAS and
down-regulates DNMT1 expression. This leads to demethylation of
CpGs in the FAS promoter resulting in activation of FAS transcrip-
tion. Subsequently apoptosis is induced in the affected neoplastic
cells. In contrast, ibandronate does not exert these effects in non-
neoplastic (immortalized) cell lines.
Epigenetic mechanisms play an important role in multiple
physiological and pathological processes [19]. Besides their use as
antiresorptive treatment for osteoporosis, bisphosphonates as
epigenetically active drugs with the potential to re-activate pro-
apoptotic genes, could gain a consolidated role in antitumor
treatment.
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